Auxilium Pharmaceuticals, Inc. (AUXL)

Negative Earnings Surprise

Rise too steep on hand disorder drug

Considering Auxiliam Pharmaceuticals has never earned money, it is simply overvalued at 45 times book value.

Release of treatment for Dupuytrens Disease

http://seekingalpha.com/article/133869-fda-clinical-trial-updates-watson-pharma-united-therapeutics-auxilium-dendreon?source=feed

AUXL has a too high valuation compared to its sales potential. It is also loss making.

Their pipeline looks more like a pipedream. They make and sell testosterone ointment, but they want us to think they have important things in the works. I see no reason to believe the cures for crooked wangs and hands will ever pan out. Moreover, even if the cures worked, the valuation looks absurd. Also I don't think they have much in the way of intellectual property protection. So this is basically a billion dollar testosterone ointment company that I expect to go nowhere.

Nice products, too much hype. How can you justify a market cap of $1.6 Billion with sales of under $100 Million? Some claim 20% annual sales growth. Even assuming they're correct, this one needs to be chopped in half before we even start to think about a fair valuation.

Show me why this is worth so much. We're into a bear market so it better be good. Meanwhile ima short this sucka

Do any investors out there know anything about Dupuytren's contracture? It is not very common. Most patients who need intervention would be referred to an orthopedic surgeon. If Xiaflex were actually FDA approved, the surgeon could recommend either fixing the problem surgically or trying injections of a new agent that would require multiple visits and doesn't always work.

With regard to insurance company payment, with surgery, they pay a physician fee for the operation and a hospital fee for the procedure. With Xiaflex, they would pay Auxilium for the drug, the physician fee for the procedure (injection), and the hospital/clinic fee for the procedure. If the drug is priced too high or it requires multiple visits for repeat injections, the companies will not approve payment for xiaflex, and the patient will be left only with the option of surgery. If the drug is priced lower and insurance will pay for it, the surgeon will consider his physician fee for operation (high) or injection (low). Most surgeons are already biased toward performing surgery, and the financial disadvantage for choosing injection rather than operation will influence most surgeons to continue with the established standard of care which is surgery.

good stock

Xiaflex has potential to be a blockbuster drug in a niche market without many competitors ...

Overepriced with negative earnings for the foreseable future.

Also is currently a one-product company with mixed results in the whole synthetic testosterone marketplace. There are negative stories in the print press regarding the effectiveness of such products, including at least one that suggests that treatments can have the opposite of the desired effect.

I just have to be contrarian here and give this a green thumb. If you think about it, the numbers don't look too bad. Other company's doing the same thing are far less profitable. In fact thew profit here is about what SIRI's is. With all the money that must be spent on research, I think this amount negative isn't too bad. And if their products, which appear very promising so far, work and are approved, you have a big winner here. So this is my very risky pick. Don't do what I'm doing.

Auxl has a hot pipeline

This stock could triple.

But I heard they are selling popsicle sticks that you tape to your dong.

CEO is a marketer,Exec. VP, Medimmune, rather than a Doc. Already have product and in late stage with new, so marketing is important.

downside provided by testim;
other drugs in phase 3 trials;
stock could triple

Another crappy pharmaceutical company that will never earn a profit.